Clinical trial
Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic…
NCT00065260 · National Heart, Lung, and Blood Institute (NHLBI), NIH · Completed
Key facts
| NCT number | NCT00065260 |
|---|---|
| Title | Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia |
| Official title | A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment |
| Lead sponsor | National Heart, Lung, and Blood Institute (NHLBI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Aplastic Anemia |
| Intervention type | Drug |
| Interventions | Campath-1H, r-ATG, CsA |
| Enrollment | 54 |
| Start date | Nov 6, 2003 |
| Primary completion | Dec 29, 2010 |
| Completion | Feb 5, 2016 |
| First posted | Jul 21, 2003 |
| Last update posted | Jul 21, 2021 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: